Previous 10 | Next 10 |
home / stock / gild / gild articles
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings??...
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 3.77% on an annualized basis producing an average annual return...
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...
Xilio Therapeutics Inc (NASDAQ:XLO) shares are surging as the company announced an exclusive license agreement with Gilead Sciences Inc&n...
Gilead Sciences Inc’s (NASDAQ:GILD) executive revealed the company’s plans to increase its production of cell therapy cancer treat...
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 4.71% on an annualized basis producing an average annual return...
Morgan Stanley initiates Arcellx Inc (NASDAQ:ACLX), noting a differentiated CAR-T platform for blood cancer backed by an established...
Gilead Sciences Inc (NASDAQ:GILD) and Merck & Co Inc (NYSE:MRK) released results from the Phase 2 clinical study evaluating the ...
Biogen Inc (NASDAQ:BIIB) released interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study. The Ph...
News, Short Squeeze, Breakout and More Instantly...
– RADIAN’s Five-Year, $25 Million Extension Will Increase Support for Local Organizations and Drive Progress to Help Turn the Tide on HIV Across the Region – – RADIAN Will Expand Geographic Focus to Provide Key Populations and Communities Im...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company early next year. While the company works to identify a successor, Dr. Parsey will continue as Chief Medical Officer until the first quarter of 2025 and support this trans...